Related references
Note: Only part of the references are listed.Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas
Iwona Wlodarska et al.
BLOOD (2008)
Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma
Daan Dierickx et al.
LEUKEMIA & LYMPHOMA (2008)
Therapeutic options in mantle cell lymphoma
Saar Gill et al.
LEUKEMIA & LYMPHOMA (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
D. S. Ritchie et al.
ANNALS OF HEMATOLOGY (2007)
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
V. Boehme et al.
ANNALS OF ONCOLOGY (2007)
Cyclin D1-negative mantle cell lymphoma:: a clinicopathologic study based on gene expression profiling
K Fu et al.
BLOOD (2005)
Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: A primary low-grade CNS lymphoma that mimics meningioma
PH Tu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group
E Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cerebrospinal fluid involvement in mantle cell lymphoma
R Valdez et al.
MODERN PATHOLOGY (2002)
Share Paper
